RE: NCI update24 Jun 2026 13:50
Apogee Therapeutics: Acquired by AbbVie in a $10.9 billion deal, gaining access to their next-generation half-life extended monoclonal antibodies (like the IL-13 inhibitor zumilokibart) for atopic dermatitis and asthma.Firefly Bio: Acquired by Johnson & Johnson for $1 billion to secure their degrader antibody conjugate (DAC) platform for oncology.RayThera: Acquired by Biogen for up to $1 billion to expand their early-stage immunology and immune disease pipeline.Tubulis: Acquired by Gilead Sciences to boost their cancer-fighting antibody-drug conjugate (ADC) capabilities.Candid Therapeutics: Acquired by UCB to add next-generation BCMA T-cell engager therapies to their immunology portfolio.CrossBridge Bio: Acquired by Eli Lilly for up to $300 million to expand their preclinical pipeline with next-generation ADC technology.